Home › Trials › NCT06562777
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Observing sex differences in symptoms during cancer immunotherapy

Official title: INvestigating Sex and Gender-Related Differences in Immunotherapy Treatment Effects (INSITE)

Run by OHSU Knight Cancer Institute · NCT06562777 · Data updated 2026-11-12

This study looks at the different symptoms men and women experience during cancer immunotherapy to see how their reports match up with what doctors observe.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorOHSU Knight Cancer Institute
Academic / other
Drugs / interventionschemotherapy, immunotherapy, radiation
Locations1 site (Portland, Oregon)
StatusRecruiting
StartedSeptember 15, 2023
Main results expectedMarch 1, 2027
Study endsMarch 1, 2027
Registry record updatedSeptember 8, 2026
Trial IDNCT06562777 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a confirmed cancer diagnosis who are about to start standard of care immunotherapy.

Probably not a fit

Patients diagnosed with breast, prostate, testicular, penile, or gynecologic cancers may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to understand the symptoms experienced by patients undergoing immunotherapy for cancer, focusing on sex differences in these symptoms. The primary objectives include characterizing immune-related adverse events reported by patients and assessing the discrepancies between clinician evaluations and patient reports based on gender. Patients will complete surveys and have their medical records reviewed to gather comprehensive data on their experiences during treatment. The study is non-interventional and relies on patient-reported outcomes and clinical assessments.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of how immunotherapy affects different genders, leading to improved patient care and tailored treatment approaches.

How similar studies have gone: While there is ongoing research into sex differences in cancer treatment responses, this specific observational approach focusing on immunotherapy symptoms is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age 18 years or older on date of enrollment (Confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
2. Histologically confirmed diagnosis of cancer and plan to begin SOC immunotherapy for the treatment of cancer per FDA approval and/or National Comprehensive Cancer Network (NCCN) guidelines (Confirmed by review of cancer diagnosis and treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
3. Treating oncologist anticipates at least 6 consecutive months of SOC immunotherapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)

Exclusion Criteria:

1. Diagnosed with breast, prostate, testicular, penile, or gynecologic cancer (Confirmed by review of the cancer diagnosis as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
2. Previously received immunotherapy (Confirmed by review of cancer treatment history as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
3. Life expectancy of \<6 months at time of enrollment per the treating oncologist (Confirmed by the professional opinion of the treating oncologist and subsequently recorded in a CRF.)
4. Concurrently receiving a non-immunotherapy treatment, including chemotherapy, biological, or targeted therapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
5. Concurrently receiving radiation, unless hypofractionated palliative radiation prescribed to alleviate poorly controlled symptoms (e.g. pain) (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
6. Participation in a clinical trial of experimental immunotherapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
7. Needs to rely on a proxy to complete patient-reported outcome instruments (Confirmed by self-report on Health History Questionnaire.)
8. Unwilling or unable to complete consent form and surveys electronically (Confirmed by successful completion of electronic consent form and baseline survey in REDCap.)

Assessment of participant eligibility is at the discretion of the Principal Investigator, Dr. Deanne Tibbitts.

Where it's running

  • OHSU Knight Cancer Institute
    Portland, Oregon, United States     Recruiting

Study contacts

  • Principal investigator: Deanne Tibbitts — OHSU Knight Cancer Institute

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hematopoietic and Lymphatic System Neoplasm 55Malignant Solid Neoplasm 97OHSU Knight Cancer Institute 37
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.